Recent Updates
Recently added Catalysts
SNDL Negative Sentiment Score: 25/100

SNDL Inc. Condensed Consolidated Interim Financial Statements For the three and six months ended

Key Takeaway: SNDL Inc. has reported its condensed consolidated interim financial statements for the three and six months ended June 30, 2023. The company experienced a net loss of CAD 33.2 million during this period, a considerable decrease from previous losses, alongside a revenue increase. Notably, administrative expenses rose significantly, impacting profitability despite a boost in net revenue. The overall financial position appears under stress with increased liabilities and negative comprehensive income reported.

Market Sentiment Analysis

POSITIVE FACTORS

  • Net revenue increased compared to the same period in 2022.
  • Cost of sales has shown some control compared to the gross revenue growth.
  • Inventory levels have increased, indicating potential for future sales.

CONCERNS & RISKS

  • The company reported a significant net loss of CAD 33,158,000.
  • General and administrative expenses are notably high at CAD 52,727,000.
  • Losses from discontinued operations have increased compared to the prior period.

Full Press Release Details

Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited expressed in thousands of Canadian dollars)
Condensed Consolidated Interim Statement of Financial Position
(Unaudited - expressed in thousands of Canadian dollars)
As at Note June 30, 2023 December 31, 2022
Assets
Current assets
Cash and cash equivalents 185,455 279,586
Restricted cash 19,456 19,338
Marketable securities 6 3,535 21,926
Accounts receivable 32,661 22,636
Biological assets 7 1,330 3,477
Inventory 8 160,407 127,782
Prepaid expenses and deposits 21,792 10,110
Investments 14 23,038 6,552
Assets held for sale 3(a),9 8,391 6,375
Net investment in subleases 12 3,656 3,701
459,721 501,483
Non-current assets
Long-term deposits 9,766 8,584
Right of use assets 10 136,947 134,154
Property, plant and equipment 11 181,841 143,409
Net investment in subleases 12 18,918 19,618
Intangible assets 13 74,446 74,885
Investments 14 9,638 90,702
Equity-accounted investees 15 532,818 519,255
Goodwill 3(a) 147,680 67,260
Total assets 1,571,775 1,559,350
Liabilities
Current liabilities
Accounts payable and accrued liabilities 62,557 48,153
Lease liabilities 17 35,982 30,206
Derivative warrants 16 3,960 11,002
102,499 89,361
Non-current liabilities
Lease liabilities 17 136,136 139,625
Other liabilities 5,252 2,709
Total liabilities 243,887 231,695
Shareholders' equity
Share capital 18(b) 2,365,845 2,292,810
Warrants 2,260 2,260
Contributed surplus 73,636 68,961
Contingent consideration 2,279 2,279
Accumulated deficit (1,156,279 ) (1,091,999 )
Accumulated other comprehensive income 20,182 32,188
Total shareholders' equity 1,307,923 1,306,499
Non-controlling interest 19,965 21,156
Total liabilities and shareholders' equity 1,571,775 1,559,350
Commitments (note 27)
Subsequent events (notes 19 and 28)
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statement of Loss and Comprehensive Loss
(Unaudited - expressed in thousands of Canadian dollars, except per share amounts)
Three months ended June 30 Six months ended June 30
Note 2023 2022 2023 2022
Gross revenue 20 257,425 227,557 470,324 247,684
Excise taxes 12,914 3,862 23,361 6,392
Net revenue 244,511 223,695 446,963 241,292
Cost of sales 8 188,922 174,291 347,071 188,617
Inventory impairment and obsolescence 8 4,291 3,871 13,468 5,852
Gross margin before fair value adjustments 51,298 45,533 86,424 46,823
Change in fair value of biological assets (1,413 ) (388 ) (4,948 ) 3,302
Change in fair value realized through inventory 2,048 (2,066 ) 2,998 (3,627 )
Gross margin 51,933 43,079 84,474 46,498
Interest and fee revenue 21 3,421 2,577 7,632 6,438
Investment loss 21 (4,020 ) (35,073 ) (9,189 ) (52,783 )
Share of profit (loss) of equity-accounted investees 15 (936 ) (37,978 ) 8,580 (33,887 )
General and administrative 52,727 40,293 101,300 50,975
Sales and marketing 4,104 3,132 7,490 4,243
Research and development 20 390 160 485
Depreciation and amortization 10,11,13 13,443 8,800 29,911 9,539
Share-based compensation 19 3,893 438 6,102 4,642
Restructuring costs 4,042 (882 ) 5,578 (882 )
Asset impairment 11,13 1,658 1,850 2,465 1,850
Loss from operations (29,489 ) (81,416 ) (61,509 ) (104,586 )
Transaction costs (173 ) 7,938 (2,213 ) 1,457
Finance costs, net 22 (2,458 ) (26,505 ) (7,631 ) (26,444 )
Change in estimate of fair value of derivative warrants 16 2,240 23,656 7,042 15,356
Foreign exchange gain (loss) (31 ) 161 (194 ) 11
Gain (loss) on disposition of assets (77 ) 402 (261 ) 402
Loss before income tax (29,988 ) (75,764 ) (64,766 ) (113,804 )
Income tax recovery 1,791 1,791
Net loss from continuing operations (29,988 ) (73,973 ) (64,766 ) (112,013 )
Net loss from discontinued operations 4 (3,170 ) (4,535 )
Net loss (33,158 ) (73,973 ) (69,301 ) (112,013 )
Equity-accounted investees - share of other comprehensive income (loss) 15 (11,621 ) 12,727 (12,006 ) 5,994
Gain on translation of foreign operations (5 )
Comprehensive loss (44,784 ) (61,246 ) (81,307 ) (106,019 )
Net loss from continuing operations attributable to:
Owners of the Company (29,350 ) (73,301 ) (63,553 ) (111,205 )
Non-controlling interest (638 ) (672 ) (1,213 ) (808 )
(29,988 ) (73,973 ) (64,766 ) (112,013 )
Net income (loss) attributable to:
Owners of the Company (32,520 ) (73,301 ) (68,088 ) (111,205 )
Non-controlling interest (638 ) (672 ) (1,213 ) (808 )
(33,158 ) (73,973 ) (69,301 ) (112,013 )
Comprehensive income (loss) attributable to:
Owners of the Company (44,146 ) (60,574 ) (80,094 ) (105,211 )
Non-controlling interest (638 ) (672 ) (1,213 ) (808 )
(44,784 ) (61,246 ) (81,307 ) (106,019 )
Net loss per common share attributable to owners of the Company
Basic and diluted 24 $ (0.12 ) $ (0.31 ) $ (0.26 ) $ (0.50 )
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statement of Changes in Shareholders' Equity
(Unaudited - expressed in thousands of Canadian dollars)
Note Share capital Warrants Contributed surplus Contingent consideration Accumulated deficit Accumulated other comprehensive income Non-controlling interest Total
Balance at December 31, 2022 2,292,810 2,260 68,961 2,279 (1,091,999 ) 32,188 21,156 1,327,655
Net loss (68,088 ) (1,213 ) (69,301 )
Other comprehensive loss (12,006 ) (12,006 )
Share repurchases 18(b) (5,344 ) 3,808 (1,536 )
Share issuances by subsidiaries 25 26 51
Acquisition 3(a) 83,953 83,953
Shares acquired and cancelled 18(b) (6,615 ) (6,615 )
Share-based compensation 19 5,691 5,691
Employee awards exercised 18(b) 1,041 (1,041 )
Distribution declared by subsidiaries (4 ) (4 )
Balance at June 30, 2023 2,365,845 2,260 73,636 2,279 (1,156,279 ) 20,182 19,965 1,327,888
Balance at March 31, 2023 2,365,319 2,260 70,716 2,279 (1,123,759 ) 31,808 20,587 1,369,210
Net loss (32,520 ) (638 ) (33,158 )
Other comprehensive income (11,626 ) (11,626 )
Share issuances by subsidiaries 37 22 59
Share-based compensation 19 3,409 3,409
Employee awards exercised 18(b) 526 (526 )
Distribution declared by subsidiaries (6 ) (6 )
Balance at June 30, 2023 2,365,845 2,260 73,636 2,279 (1,156,279 ) 20,182 19,965 1,327,888
Condensed Consolidated Interim Statement of Changes in Shareholders' Equity
(Unaudited - expressed in thousands of Canadian dollars)
Note Share capital Warrants Contributed surplus Contingent consideration Accumulated deficit Accumulated other comprehensive income Non- controlling interest Total equity
Balance at December 31, 2021 2,035,704 8,092 60,734 2,279 (785,112 ) 7,607 229 1,329,533
Net loss (111,205 ) (808 ) (112,013 )
Other comprehensive income 5,994 5,994
Share issuances 2,870 2,870
Share repurchases (5,170 ) 3,117 (2,053 )
Share issuances by subsidiaries 57 35 92
Acquisition 287,129 58,250 345,379
Share-based compensation 5,992 95 6,087
Employee awards exercised 1,740 (1,740 )
Balance at June 30, 2022 2,322,273 8,092 65,043 2,279 (893,200 ) 13,601 57,801 1,575,889
Balance at March 31, 2022 2,327,443 8,092 61,959 2,279 (823,016 ) 874 58,343 1,635,974
Net loss (73,301 ) (672 ) (73,973 )
Other comprehensive income 12,727 12,727
Share repurchases (5,170 ) 3,117 (2,053 )
Share issuances by subsidiaries 57 35 92
Share-based compensation 3,027 95 3,122
Balance at June 30, 2022 2,322,273 8,092 65,043 2,279 (893,200 ) 13,601 57,801 1,575,889
See accompanying notes to the condensed consolidated interim financial statements.
Condensed Consolidated Interim Statement of Cash Flows
(Unaudited - expressed in thousands of Canadian dollars)
Three months ended June 30 Six months ended June 30
Note 2023 2022 2023 2022
Cash provided by (used in):
Operating activities
Net loss for the period (33,158 ) (73,973 ) (69,301 ) (112,013 )
Adjustments for:
Income tax recovery (1,791 ) (1,791 )
Interest and fee revenue 21 (3,421 ) (2,577 ) (7,632 ) (6,438 )
Change in fair value of biological assets 1,413 388 4,948 (3,302 )
Share-based compensation 19 3,893 438 6,102 4,642
Depreciation and amortization 10,11,13 14,674 10,538 32,933 12,977
Loss (gain) on disposition of assets 77 (402 ) 261 (402 )
Inventory obsolescence 8 4,291 3,871 13,468 5,852
Finance costs 22 2,458 26,505 7,631 26,444
Change in estimate of fair value of derivative warrants 16 (2,240 ) (23,656 ) (7,042 ) (15,356 )
Unrealized foreign exchange loss (gain) (72 ) 19 (24 ) 35
Asset impairment 1,658 1,850 2,465 1,850
Share of (profit) loss of equity-accounted investees 15 936 37,978 (8,580 ) 33,887
Loss on settlement of marketable securities 6,21 48,988 92,792
Unrealized (gain) loss on marketable securities 6,21 (44,968 ) 35,338 (83,603 ) 53,172
Additions to marketable securities (2,899 ) (3,500 )
Proceeds from settlement of marketable securities 6 3,437 3,463
Income distributions from equity-accounted investees 685
Interest received 3,217 2,084 6,920 5,799
Change in non-cash working capital 23 (14,193 ) (31,584 ) (56,755 ) (46,434 )
Net cash used in operating activities from continuing operations (13,010 ) (17,873 ) (61,954 ) (43,893 )
Net cash provided by operating activities from discontinued operations 4 4,167 4,314
Net cash used in operating activities (8,843 ) (17,873 ) (57,640 ) (43,893 )
Investing activities
Additions to property, plant and equipment 11 (1,247 ) (3,554 ) (2,641 ) (4,535 )
Additions to intangible assets 13 (39 ) 1 (56 ) (55 )
Additions to investments 125 337 (702 ) (14,094 )
Additions to equity-accounted investees 15 (9,443 ) (36,880 ) (16,989 ) (94,200 )
Proceeds from disposal of property, plant and equipment 55 4,000 137 4,000
Acquisitions, net of cash acquired 3 3,695 (31,149 )
Change in non-cash working capital 23 1,586 294 1,127 259
Net cash used in investing activities from continuing operations (8,963 ) (35,802 ) (15,429 ) (139,774 )
Net cash used in investing activities from discontinued operations 4
Net cash used in investing activities (8,963 ) (35,802 ) (15,429 ) (139,774 )
Financing activities
Change in restricted cash (76 ) 2,541 (118 ) 7,607
Payments on lease liabilities, net (10,116 ) (9,177 ) (19,607 ) (9,624 )
Repurchase of common shares, net of costs 18(b) (2,053 ) (1,536 ) (2,053 )
Repayment of long-term debt (10,000 )
Change in non-cash working capital 23 200 2,170 199 2,116
Net cash used in financing activities from continuing operations (9,992 ) (6,519 ) (21,062 ) (11,954 )
Net cash used in financing activities from discontinued operations 4
Net cash used in financing activities (9,992 ) (6,519 ) (21,062 ) (11,954 )
Change in cash and cash equivalents (27,798 ) (60,194 ) (94,131 ) (195,621 )
Cash and cash equivalents, beginning of period 213,253 422,824 279,586 558,251
Cash and cash equivalents, end of period 185,455 362,630 185,455 362,630
See accompanying notes to the condensed consolidated interim financial statements.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
1.Description of business
SNDL Inc. ( SNDL or the Company ) was incorporated under the Business Corporations Act (Alberta) on August 19, 2006. On July 25, 2022, the Company's shareholders approved a special resolution amending the articles of SNDL to change the name of the Company from Sundial Growers Inc. to SNDL Inc. .
The Company's head office is located at 300, 919 11th Avenue SW, Calgary, Alberta, Canada.
The principal activities of the Company are the retailing of wines, beers and spirits, the operation and support of corporate-owned and franchise retail cannabis stores in Canadian jurisdictions where the private sale of recreational cannabis is permitted, the manufacturing of cannabis products providing proprietary cannabis processing services, the production, distribution and sale of cannabis domestically and for export pursuant to the Cannabis Act (Canada) (the Cannabis Act ), and the deployment of capital to investment opportunities. The Cannabis Act regulates the production, distribution, and possession of cannabis for both medical and adult recreational access in Canada. The Company also owns approximately 63% of Nova Cannabis Inc. ( Nova ) (TSX: NOVC), whose principal activities are the retail sale of cannabis.
SNDL and its subsidiaries currently operate solely in Canada, with the exception of Green Roads, Inc. ( Green Roads ), a subsidiary acquired in the Valens Transaction (defined below) who sold CBD products in the United States and is classified as held for sale (note 9) and discontinued operations (note 4). Through its joint venture, SunStream Bancorp Inc. ( SunStream ) (note 15), the Company provides growth capital that pursues indirect investment and financial services opportunities in the cannabis sector, as well as other investment opportunities. The Company also makes strategic portfolio investments in debt and equity securities.
The Company's common shares trade on the Nasdaq Capital Market ( Nasdaq ) under the ticker symbol SNDL .
2.Basis of presentation
Statement of compliance
The condensed consolidated interim financial statements ( financial statements ) have been prepared in accordance with International Accounting Standard 34 Interim Financial Reporting as issued by the International Accounting Standards Board and interpretations of the International Financial Reporting Interpretations Committee. These financial statements were prepared using the same accounting policies and methods as those disclosed in the annual consolidated financial statements for the year ended December 31, 2022. These financial statements should be read in conjunction with the annual consolidated financial statements for the Company for the year ended December 31, 2022.
These financial statements were approved and authorized for issue by the Board of Directors ( Board ) on August 11, 2023.
3.Business acquisitions
On January 17, 2023, the Company acquired all of the issued and outstanding common shares of The Valens Company Inc. ( Valens ), other than those owned by SNDL and its subsidiaries, by way of a statutory plan of arrangement (the Valens Transaction ). The Valens Transaction consideration was comprised of (i) the assumption of Valens' $60 million non-revolving term loan facility from its then existing lender, and (ii) an aggregate 27.6 million SNDL common shares valued at $84.0 million based on the fair value of each common share of the Company on the closing date (0.3334 of a SNDL common share for each Valens common share).
Notes to the Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Valens is a manufacturer of cannabis products providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Valens products are formulated for the medical, health and wellness, and recreational consumer segments.
The Company has engaged independent valuation experts to assist in determining the fair value of certain assets acquired and liabilities assumed and related deferred income tax impacts. The purchase price allocation is not final as the Company is continuing to obtain and verify information required to determine the fair value of certain assets and liabilities and the amount of deferred income taxes, if any, arising on their recognition.
Due to the inherent complexity associated with valuations and the timing of the acquisition, the amounts below are provisional and subject to adjustment.
The fair value of consideration paid was as follows:
Provisional Adjustments Provisional
Valens loan facility 61,512 61,512
Issuance of common shares 83,953 83,953
145,465 145,465
The preliminary fair value of the assets and liabilities acquired was as follows:
Provisional Adjustments Provisional
Cash 3,615 3,615
Accounts receivable 21,361 21,361
Investments 876 876
Prepaid expenses and deposits 4,980 4,980
Inventory 14,140 14,140
Assets held for sale 6,330 6,330
Right of use assets 2,882 2,882
Property, plant and equipment 63,030 (10,938 ) 52,092
Intangible assets 2,285 (785 ) 1,500
Goodwill 68,697 11,723 80,420
Accounts payable and accrued liabilities (34,185 ) (34,185 )
Contractual obligation (5,339 ) (5,339 )
Lease liabilities (3,207 ) (3,207 )
145,465 145,465
As new information is obtained within one year of the date of acquisition, about facts and circumstances that existed at the date of acquisition, identifies adjustments to the above amounts, the accounting for the acquisition will be revised.
Valens subsidiary Green Roads was sold and has been classified as held for sale and discontinued operations (note 4).
The financial statements incorporate the operations of Valens commencing January 18, 2023. During the period January 18, 2023 to June 30, 2023 the Company recorded revenues of $39.1 million and net loss of $25.8 million from the Valens operations. Had the Valens Transaction closed on January 1, 2023, management estimates that for the period January 1, 2023, to January 17, 2023, revenue would have increased by $4.2 million and net loss would have increased by $2.1 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2023.
The Company incurred costs related to the Valens Transaction of $2.6 million which have been included in transaction costs.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
On February 7, 2023, the Company acquired the right, title and interest in (i) five Superette retail locations within Toronto and Ottawa; (ii) the intellectual property rights related to the Superette brand (the Superette IP ); and (iii) the shares of Superette Ontario (collectively, the Superette Transaction ).
The Superette acquisition consideration was comprised of the extinguishment of the Company's promissory note.
The fair value of consideration paid was as follows:
Extinguishment of promissory note 2,625
2,625
The fair value of the assets and liabilities acquired was as follows:
Cash 80
Accounts receivable 30
Prepaid expenses and deposits 141
Inventory 371
Right of use assets 1,129
Property, plant and equipment 2,077
Accounts payable and accrued liabilities (74 )
Lease liabilities (1,129 )
2,625
The financial statements incorporate the operations of Superette commencing February 8, 2023. During the period February 8, 2023 to June 30, 2023 the Company recorded revenues of $1.7 million and net loss of $0.7 million from the Superette operations. Had the Superette Transaction closed on January 1, 2023, management estimates that for the period January 1, 2023, to February 7, 2023, revenue would have increased by $0.5 million and net loss would have increased by $0.1 million. In determining these amounts, management assumes the fair values on the date of acquisition would have been the same as if the acquisition had occurred on January 1, 2023.
The Company incurred costs related to the Superette Transaction of $0.6 million which have been included in transaction costs.
4.Discontinued operations
The Green Roads operations acquired as part of the Valens acquisition were classified as held for sale and discontinued operations as the carrying amount of the disposal group was expected to be recovered through a sale transaction rather than through continued use.
Green Roads filed for bankruptcy on March 6, 2023. Subject to the bid procedures, a successful bid of USD$3.1 million was accepted and the sale was approved at a court hearing on May 10, 2023. The disposition of Green Roads closed on May 31, 2023 and a loss on disposition of $2.3 million was recorded.
The consolidated statement of loss and comprehensive loss and consolidated statement of cash flows have been presented to show the discontinued operations separately from continuing operations.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Results of discontinued operations
Three months ended June 30 Six months ended June 30
2023 2022 2023 2022
Net revenue 2,978 7,510
Cost of sales 1,640 3,841
Gross margin 1,338 3,669
General and administrative 1,302 3,639
Sales and marketing 687 1,817
Depreciation and amortization 231 450
Loss from operations (882 ) (2,237 )
Finance costs (6 ) (16 )
Loss on disposition (2,282 ) (2,282 )
Net loss (3,170 ) (4,535 )
5.Segment information
The Company's reportable segments are organized by business line and are comprised of four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments.
Liquor retail includes the sale of wines, beers and spirits through owned liquor stores. Cannabis retail includes the private sale of adult-use cannabis through owned and franchise retail cannabis stores. Cannabis operations include the cultivation, distribution and sale of cannabis for the adult-use and medical markets domestically and for export, and providing proprietary cannabis processing services, in addition to product development, manufacturing, and commercialization of cannabis consumer packaged goods. Investments include the deployment of capital to investment opportunities. Certain overhead expenses not directly attributable to any operating segment are reported as Corporate .
Notes to the Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Liquor Retail Cannabis Retail (1) Cannabis Operations (2) Investments (3) Corporate Total
As at June 30, 2023
Total assets 339,097 204,016 318,028 691,178 19,456 1,571,775
Six months ended June 30, 2023
Net revenue 267,601 139,289 40,073 446,963
Gross margin 61,627 33,599 (10,752 ) 84,474
Interest and fee revenue 58 7,397 177 7,632
Investment (loss) income (497 ) (8,692 ) (9,189 )
Share of profit (loss) of equity-accounted investees 8,580 8,580
Depreciation and amortization 18,507 7,051 1,796 2,557 29,911
Earnings (loss) from operations 6,271 2,287 (32,821 ) 7,077 (44,323 ) (61,509 )
Income (loss) before income tax 3,751 477 (32,951 ) 3,453 (39,496 ) (64,766 )
Three months ended June 30, 2023
Net revenue 151,690 71,881 20,940 244,511
Gross margin 35,360 17,780 (1,207 ) 51,933
Interest and fee revenue 58 3,186 177 3,421
Investment (loss) income (214 ) (3,806 ) (4,020 )
Share of profit (loss) of equity-accounted investees (936 ) (936 )
Depreciation and amortization 8,161 3,361 650 1,271 13,443
Earnings (loss) from operations 8,207 2,340 (14,134 ) (1,660 ) (24,242 ) (29,489 )
Income (loss) before income tax 6,714 1,221 (13,831 ) (1,917 ) (22,175 ) (29,988 )
(1)Cannabis retail includes the operations of Superette for the period February 8, 2023 to June 30, 2023.
(2)Cannabis operations includes the operations of Valens for the period January 18, 2023 to June 30, 2023.
(3)Total assets include cash and cash equivalents.
Liquor Retail (1) Cannabis Retail (1) Cannabis Operations Investments (2) Corporate Total
As at December 31, 2022
Total assets 351,338 200,393 163,130 825,151 19,338 1,559,350
Six months ended June 30, 2022
Net revenue 149,947 71,006 20,339 241,292
Gross margin 33,812 17,190 (4,504 ) 46,498
Interest and fee revenue 6,438 6,438
Investment loss (52,783 ) (52,783 )
Share of profit (loss) of equity-accounted investees (33,887 ) (33,887 )
Depreciation and amortization 2,799 2,842 9 3,889 9,539
Earnings (loss) from operations 11,215 1,196 (11,257 ) (79,668 ) (26,072 ) (104,586 )
Income (loss) before income tax 8,306 167 (11,000 ) (101,973 ) (9,304 ) (113,804 )
Three months ended June 30, 2022
Net revenue 148,637 63,494 11,564 223,695
Gross margin 33,528 13,897 (4,346 ) 43,079
Interest and fee revenue 2,577 2,577
Investment loss (35,073 ) (35,073 )
Share of profit (loss) of equity-accounted investees (37,978 ) (37,978 )
Depreciation and amortization 2,799 2,247 3,754 8,800
Earnings (loss) from operations 11,288 1,476 (8,293 ) (69,973 ) (15,914 ) (81,416 )
Income (loss) before income tax 8,379 447 (8,036 ) (92,278 ) 15,724 (75,764 )
(1)Liquor retail includes operations of Alcanna Inc. ( Alcanna ) retail stores for the period March 31, 2022 to June 30, 2022, and cannabis retail includes operations of Nova retail stores for the period March 31, 2022 to June 30, 2022.
(2)Total assets include cash and cash equivalents.
Notes to the Condensed Consolidated Interim Financial Statements
For the three and six months ended June 30, 2023
(Unaudited, expressed in thousands of Canadian dollars, except where otherwise noted)
Geographical disclosure
As at June 30, 2023, the Company had non-current assets related to investment credit operations in the United States of $532.8 million (December 31, 2022 $519.3 million). For the six months ended June 30, 2023, share of profit of equity-accounted investees related to operations in the United States was a gain of $8.6 million (six months ended June 30, 2022 loss of $33.9 million). All other non-current assets relate to operations in Canada and revenues from external customers relate to operations in Canada.
6.Marketable securities
As at June 30, 2023 December 31, 2022
Balance, beginning of year 21,926 83,724
Acquisition (note 3(a)) 876
Additions 3,755
Dispositions (10,078 )
Change in fair value recognized in profit or loss (9,189 ) (65,553 )
Balance, end of period 3,535 21,926
The Company's biological assets consist of cannabis plants in various stages of vegetation, including plants which have not been harvested. The change in carrying value of biological assets is as follows:
As at June 30, 2023 December 31, 2022
Balance, beginning of year 3,477 4,410
Increase in biological assets due to capitalized costs 15,214 27,749
Acquisition 909
Net change in fair value of biological assets (4,948 ) (1,309 )
Transferred to inventory upon harvest (12,413 ) (28,282 )
Balance, end of period 1,330 3,477
Biological assets are valued in accordance with IAS 41 and are presented at their fair value less costs to sell up to the point of harvest. This is determined using a model which estimates the expected harvest yield in grams for plants currently being cultivated, and then adjusts that amount for the expected selling price less costs to produce and sell per gram.
The fair value measurements for biological assets have been categorized as Level 3 fair values based on the inputs to the valuation technique used. The Company's method of accounting for biological assets attributes value accretion on a straight-line basis throughout the life of the biological asset from initial cloning to the point of harvest.
Management believes the most significant unobservable inputs and their impact on fair value of biological assets are as follows:
Assumption Input Weighted average input Effect of 10% change ($000s)
June 30 2023 December 31 2022 June 30 2023 December 31 2022
Yield per square foot of growing space (1) Grams 48 48 83 279
Average net selling price (2) $/gram 5.62 4.66 221 687
After harvest cost to complete and sell $/gram 1.15 1.27 47 187
(1)Varies by strain; obtained through historical growing results or grower estimate if historical results are not available.

Frequently Asked Questions

What is the total asset value as of June 30, 2023?

The total asset value is 1,571,775 thousand Canadian dollars.

How much was the net revenue for six months ended June 30, 2023?

The net revenue for six months ended June 30, 2023, was 446,963 thousand dollars.

What was the net loss from continuing operations in Q2 2023?

The net loss from continuing operations in Q2 2023 was 29,988 thousand dollars.

What is the company's shareholders' equity as of June 30, 2023?

The shareholders' equity is 1,307,923 thousand Canadian dollars.

What was the gross margin for the six months ended June 30, 2023?

The gross margin for the six months ended June 30, 2023, was 84,474 thousand dollars.

Last updated: Aug 14, 2023